Featured Research

from universities, journals, and other organizations

Hallucinogen can safely ease anxiety in advanced-stage cancer patients, study suggests

Date:
September 7, 2010
Source:
Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center (LA BioMed)
Summary:
In the first human study of its kind to be published in more than 35 years, researchers found psilocybin, an hallucinogen which occurs naturally in "magic mushrooms," can safely improve the moods of patients with advanced-stage cancer and anxiety.

In the first human study of its kind to be published in more than 35 years, researchers found psilocybin, an hallucinogen which occurs naturally in "magic mushrooms," can safely improve the moods of patients with advanced-stage cancer and anxiety, according to an article published online September 6 in the Archives of General Psychiatry.

Patients enrolled in the study at the Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center (LA BioMed) demonstrated improvement of mood and reduction of anxiety up to six months after undergoing treatment, with significance reached at the six-month point on the "Beck Depression Inventory" and at one and three months on the "State-Trait Anxiety Inventory." A third screening tool, the "Profile of Mood States," identified mood improvement after treatment that approached but did not reach significance.

"We are working with a patient population that often does not respond well to conventional treatments," said Charles S. Grob, MD, an LA BioMed principal investigator who led the research team. "Following their treatments with psilocybin, the patients and their families reported benefit from the use of this hallucinogen in reducing their anxiety. This study shows psilocybin can be administered safely, and that further investigation of hallucinogens should be pursued to determine their potential benefits."

Researchers conducted extensive investigations of psychedelic drugs in the 1950s and 1960s and found promising improvements in mood and anxiety, as well as a diminished need for narcotic pain medication among advanced-stage cancer patients. The research was abandoned in the early 1970s in the wake of widespread recreational usage that led to stiff federal laws regulating hallucinogens.

"Political and cultural pressures forced an end to these studies in the 1970s," said Dr. Grob. "We were able to revive this research under strict federal supervision and demonstrate that this is a field of study with great promise for alleviating anxiety and other psychiatric symptoms."

The LA BioMed study is the first research publication in several decades to examine the hallucinogen treatment model with advanced-cancer anxiety. Twelve volunteers, ages 36 to 58, with advanced-stage cancer and anxiety were given a moderate dose of 0.2 mg/kg of psilocybin and, on a separate occasion, a placebo. Neither the volunteers nor the researchers monitoring them knew whether they'd been given a placebo or psilocybin.

The two experimental sessions took place several weeks apart in a hospital clinical research unit at Harbor-UCLA Medical Center, where Dr. Grob is a professor of psychiatry. The research volunteers were monitored for the six hours following their dose. The volunteers were encouraged to lie in bed, wear eye shades and listen to music during the first few hours after ingesting the medication or the placebo. They were interviewed after the six-hour session and over the next six months to assess the outcome of the treatment.

This study was funded by the Heffter Research Institute, the Betsy Gordon Foundation and the Nathan Cummings Foundation (with the support and encouragement of James R. Cummings). Infrastructural support for this study was provided via grant M01-RR00425 from the National Institutes of Health for the General Clinical Research Unit at LA BioMed.


Story Source:

The above story is based on materials provided by Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center (LA BioMed). Note: Materials may be edited for content and length.


Journal Reference:

  1. Charles S. Grob, MD; Alicia L. Danforth, MA; Gurpreet S. Chopra, MD; Marycie Hagerty, RN, BSN, MA; Charles R. McKay, MD; Adam L. Halberstadt, PhD; George R. Greer, MD. Pilot Study of Psilocybin Treatment for Anxiety in Patients With Advanced-Stage Cancer. Arch Gen Psychiatry, Online September 6, 2010 DOI: 10.1001/archgenpsychiatry.2010.116

Cite This Page:

Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center (LA BioMed). "Hallucinogen can safely ease anxiety in advanced-stage cancer patients, study suggests." ScienceDaily. ScienceDaily, 7 September 2010. <www.sciencedaily.com/releases/2010/09/100906202905.htm>.
Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center (LA BioMed). (2010, September 7). Hallucinogen can safely ease anxiety in advanced-stage cancer patients, study suggests. ScienceDaily. Retrieved September 14, 2014 from www.sciencedaily.com/releases/2010/09/100906202905.htm
Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center (LA BioMed). "Hallucinogen can safely ease anxiety in advanced-stage cancer patients, study suggests." ScienceDaily. www.sciencedaily.com/releases/2010/09/100906202905.htm (accessed September 14, 2014).

Share This



More Mind & Brain News

Sunday, September 14, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Shocker: Journalists Are Utterly Addicted To Coffee

Shocker: Journalists Are Utterly Addicted To Coffee

Newsy (Sep. 13, 2014) A U.K. survey found that journalists consumed the most amount of coffee, but that's only the tip of the coffee-related statistics iceberg. Video provided by Newsy
Powered by NewsLook.com
'Magic Mushrooms' Could Help Smokers Quit

'Magic Mushrooms' Could Help Smokers Quit

Newsy (Sep. 11, 2014) In a small study, researchers found that the majority of long-time smokers quit after taking psilocybin pills and undergoing therapy sessions. Video provided by Newsy
Powered by NewsLook.com
'Fat Shaming' Might Actually Cause Weight Gain

'Fat Shaming' Might Actually Cause Weight Gain

Newsy (Sep. 11, 2014) A study for University College London suggests obese people who are discriminated against gain more weight than those who are not. Video provided by Newsy
Powered by NewsLook.com
Common Sleeping, Anxiety Pills Linked To Alzheimer's

Common Sleeping, Anxiety Pills Linked To Alzheimer's

Newsy (Sep. 10, 2014) Researchers found commonly prescribed sleeping and anxiety pills such as Xanax and Valium could lead to an increased risk for Alzheimer's disease. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

    Technology News



    Save/Print:
    Share:

    Free Subscriptions


    Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

    Get Social & Mobile


    Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

    Have Feedback?


    Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
    Mobile: iPhone Android Web
    Follow: Facebook Twitter Google+
    Subscribe: RSS Feeds Email Newsletters
    Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins